AR029775A1 - Derivados de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2-sustituidas, procedimiento para su preparacion, formas cristalinas de los mismos y metodo de tratamiento de la aterosclerosis que lo utiliza - Google Patents

Derivados de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2-sustituidas, procedimiento para su preparacion, formas cristalinas de los mismos y metodo de tratamiento de la aterosclerosis que lo utiliza

Info

Publication number
AR029775A1
AR029775A1 ARP000106287A ARP000106287A AR029775A1 AR 029775 A1 AR029775 A1 AR 029775A1 AR P000106287 A ARP000106287 A AR P000106287A AR P000106287 A ARP000106287 A AR P000106287A AR 029775 A1 AR029775 A1 AR 029775A1
Authority
AR
Argentina
Prior art keywords
treatment
crystalline forms
tetrahydrochinolines
carboxyamin
aterosclerosis
Prior art date
Application number
ARP000106287A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR029775A1 publication Critical patent/AR029775A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP000106287A 1999-11-30 2000-11-29 Derivados de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2-sustituidas, procedimiento para su preparacion, formas cristalinas de los mismos y metodo de tratamiento de la aterosclerosis que lo utiliza AR029775A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16796799P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
AR029775A1 true AR029775A1 (es) 2003-07-16

Family

ID=22609556

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106287A AR029775A1 (es) 1999-11-30 2000-11-29 Derivados de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2-sustituidas, procedimiento para su preparacion, formas cristalinas de los mismos y metodo de tratamiento de la aterosclerosis que lo utiliza

Country Status (44)

Country Link
US (1) US6313142B1 (enExample)
EP (1) EP1125929B1 (enExample)
JP (1) JP3579345B2 (enExample)
KR (1) KR100408177B1 (enExample)
CN (1) CN1173953C (enExample)
AP (1) AP2000002011A0 (enExample)
AR (1) AR029775A1 (enExample)
AT (1) ATE315028T1 (enExample)
AU (1) AU784694B2 (enExample)
BG (1) BG105009A (enExample)
BR (1) BR0005636A (enExample)
CA (1) CA2327029C (enExample)
CO (1) CO5261552A1 (enExample)
CY (1) CY1104989T1 (enExample)
CZ (1) CZ20004407A3 (enExample)
DE (1) DE60025317T2 (enExample)
DK (1) DK1125929T3 (enExample)
DZ (1) DZ3079A1 (enExample)
EA (1) EA003668B1 (enExample)
EE (1) EE200000659A (enExample)
ES (1) ES2254109T3 (enExample)
GE (1) GEP20022798B (enExample)
GT (1) GT200000190A (enExample)
HN (1) HN2000000203A (enExample)
HR (1) HRP20000804A2 (enExample)
HU (1) HUP0004747A3 (enExample)
ID (1) ID28489A (enExample)
IL (1) IL139849A (enExample)
IS (1) IS5715A (enExample)
MA (1) MA25223A1 (enExample)
NO (1) NO20006039L (enExample)
NZ (1) NZ508509A (enExample)
OA (1) OA11494A (enExample)
PA (1) PA8503801A1 (enExample)
PE (1) PE20010913A1 (enExample)
PL (1) PL344208A1 (enExample)
SG (1) SG102603A1 (enExample)
SK (1) SK17792000A3 (enExample)
TN (1) TNSN00230A1 (enExample)
TW (1) TW591016B (enExample)
UA (1) UA65615C2 (enExample)
UY (1) UY26451A1 (enExample)
YU (1) YU71500A (enExample)
ZA (1) ZA200006947B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
IL162533A0 (en) * 2001-12-19 2005-11-20 Atherogenics Inc Chalcone derivatives and their use to treat diseases
WO2003053359A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
ATE410521T1 (de) * 2002-04-11 2008-10-15 Roar Holding Llc Ex-vivo-verfahren zur bestimmung der cetp- aktivität und der wirksamkeit der behandlung von herzerkrankungen
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
PL376156A1 (en) * 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
WO2004056727A2 (en) * 2002-12-19 2004-07-08 Atherogenics, Inc. Process of making chalcone derivatives
EP1961419B1 (en) 2002-12-20 2010-03-24 Pfizer Products Inc. Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EP1601655A2 (en) * 2003-03-04 2005-12-07 Takasago International Corporation Method for producing optically active amines
AU2004222436A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
PT1603553E (pt) * 2003-03-17 2012-02-03 Japan Tobacco Inc Composições farmacêuticas de inibidores de cetp
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
PL1670768T3 (pl) * 2003-10-08 2010-01-29 Lilly Co Eli Związki i sposoby leczenia dyslipidemii
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
WO2006069162A1 (en) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
BRPI0608553A2 (pt) * 2005-02-24 2010-01-12 Millennium Pharm Inc antagonistas de receptor de pgd2 para o tratamento de doenças inflamatórias
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
TW200901959A (en) 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
CN101429160B (zh) * 2007-11-06 2011-10-19 上海药明康德新药开发有限公司 一种1-r-4-氨基-1,2,3,4-四氢喹啉的合成方法
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
PE20251749A1 (es) 2022-07-05 2025-07-09 Newamsterdam Pharma B V Sales de obicetrapib y procesos para su fabricacion y productos intermedios de estos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7870M (enExample) * 1968-11-08 1970-04-27
US3971789A (en) 1972-10-21 1976-07-27 John Wyeth & Brother Limited O-(4-Quinolylamino)benzamides
GB8432091D0 (en) 1984-12-19 1985-01-30 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US4839368A (en) 1986-05-02 1989-06-13 Mochida Pharmaceutical Co., Ltd. 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivatives
GB8804444D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.

Also Published As

Publication number Publication date
PE20010913A1 (es) 2001-09-10
DZ3079A1 (fr) 2004-10-24
CA2327029A1 (en) 2001-05-30
HUP0004747A2 (hu) 2001-10-28
EA200001129A3 (ru) 2001-10-22
EE200000659A (et) 2001-08-15
IL139849A0 (en) 2002-02-10
YU71500A (sh) 2003-02-28
DE60025317T2 (de) 2006-08-03
PL344208A1 (en) 2001-06-04
MA25223A1 (fr) 2001-07-02
EP1125929B1 (en) 2006-01-04
UA65615C2 (uk) 2004-04-15
JP3579345B2 (ja) 2004-10-20
NO20006039D0 (no) 2000-11-29
EA003668B1 (ru) 2003-08-28
DK1125929T3 (da) 2006-04-03
HN2000000203A (es) 2001-06-13
JP2001163859A (ja) 2001-06-19
CO5261552A1 (es) 2003-03-31
ES2254109T3 (es) 2006-06-16
CZ20004407A3 (cs) 2002-06-12
US6313142B1 (en) 2001-11-06
ID28489A (id) 2001-05-31
SK17792000A3 (sk) 2002-10-08
AP2000002011A0 (en) 2000-12-31
KR20010052012A (ko) 2001-06-25
OA11494A (en) 2004-05-07
ATE315028T1 (de) 2006-02-15
CA2327029C (en) 2005-08-09
AU784694B2 (en) 2006-06-01
ZA200006947B (en) 2002-05-27
HUP0004747A3 (en) 2002-12-28
SG102603A1 (en) 2004-03-26
HU0004747D0 (enExample) 2001-02-28
NO20006039L (no) 2001-05-31
DE60025317D1 (de) 2006-03-30
BR0005636A (pt) 2001-07-17
EP1125929A1 (en) 2001-08-22
CN1173953C (zh) 2004-11-03
GEP20022798B (en) 2002-09-25
PA8503801A1 (es) 2002-07-30
TNSN00230A1 (fr) 2005-11-10
CY1104989T1 (el) 2010-03-03
HRP20000804A2 (en) 2001-06-30
GT200000190A (es) 2002-04-27
NZ508509A (en) 2001-06-29
KR100408177B1 (ko) 2003-12-01
IL139849A (en) 2006-10-31
TW591016B (en) 2004-06-11
UY26451A1 (es) 2001-06-29
IS5715A (is) 2001-05-31
HK1038007A1 (en) 2002-03-01
BG105009A (en) 2001-11-30
AU7178900A (en) 2001-05-31
CN1302800A (zh) 2001-07-11
EA200001129A2 (ru) 2001-06-25

Similar Documents

Publication Publication Date Title
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
NO972043D0 (no) Tienopyridin eller tienopyrimidinderivater og deres anvendelse
CY1108041T1 (el) Αναστολεις της rho-κινασης
CY1105915T1 (el) Παραγωγα θειαζολιου για τη θepαπεια των παθησεων που σχετιζονται με τους ppar
CY1109227T1 (el) Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων
AR026173A1 (es) Inhibidores de neuraminidasas.
UY27234A1 (es) Inhibidores novedosos de tirosina cinasa
AR007640A1 (es) DERIVADOS DE FENILALANINA, PROCEDIMIENTO PARA PREPARARLOS, PREPARACIONES FARMACEUTICAS QUE LOS CONTIENEN Y EMPLEO DE LOS MISMOS PARA PREPARAR UNMEDICAMENTO QUE ACTUA COMO INHIBIDOR DE LA INTEGRINA ALFA(v)
ES2148229T3 (es) Eteres y tioeteres en la posicion 17 de 4-aza-esteroides.
BR9916894A (pt) ácidos sulfohidroxâmicos e sulfohidroxamatos eseu uso como inibidores de mek
PT1115695E (pt) (n+1) -alcanois 1-aminossubstituidos (r) -quirais halogenados uteis para inibir a actividade da proteina de transferencia de ester de colesterilo
MX9702175A (es) Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol.
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
PT1140184E (pt) Combinacoes de inibidores de proteina de transferencia de ester de colesterilo com derivados de acido nicotinico para indicacoes cardiovasculares
NO20065784L (no) Steroidforbindelser og anvendelse av slike
MX9207449A (es) Inhibidores de la enzima proteolitica derivada de sacarina.
ES2013801A6 (es) Procedimiento de preparacion de derivados de 4h-1-benzopiran-4-ona o sus sales.
UY27842A1 (es) Fluorobenzamidas
AR029214A1 (es) Compuestos inhibidores de fosfodiesterasa - 4: 8 - arilquinolinas sustituidas, composiciones farmaceuticas, metodo de tratamiento que las utiliza
DK0623121T3 (da) Fremstilling af N-acetylneuraminsyrederivater
TR199902257T2 (xx) Tetrahidropirido bile�ikleri
ES2155621T3 (es) Derivados azo del acido 5-aminosalicilico para el tratamiento de la enfermedad inflamatoria intestinal.
DE69908644D1 (de) Kombnationen von cholesteryl ester transfer protein inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
CO5011061A1 (es) Inhibicion de las metaloprotesas de matriz por acidos biariloxobutiricos sustituidos y composiciones farmaceuticas que los contienen
AR038332A1 (es) Compuestos que son metabolitos del acido (3-{[(4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi) acetico, composiciones farmaceuticas que los contienen, y procedimiento de determinacion

Legal Events

Date Code Title Description
FB Suspension of granting procedure